Our memories of Mahabaleswar. CDC - Immunization Update 2006 Satellite Internet Broadcast December,...
-
Upload
morris-nelson -
Category
Documents
-
view
218 -
download
3
Transcript of Our memories of Mahabaleswar. CDC - Immunization Update 2006 Satellite Internet Broadcast December,...
Our memories of
Mahabaleswar
CDC - Immunization Update 2006Satellite Internet Broadcast
December, 2006
Cervical Cancer Vaccine - HPV
Summarized from the CDC Broadcast by Dr. R.V.S.N.Sarma. M.D., M.Sc.,
Cervical Cancer
• Cervical cancer is the 2nd leading cancer amongst women worldwide
• 500,000 new cases and 300,000 deaths due to Ca Cx
• >99% related to human papilloma virus (HPV) infec.
• HPV infect epithelial cells including the genital tract
• HPV type 16 related to half of these cases• HPV –18, -45, -31, -33, -52, -58 and -35
together with HPV-16 responsible for 90% of all cervical cancers worldwide
Human Papillomavirus
• More than 100 types– More than 60 cutaneous types
Can lead to skin warts– 40 mucosal types
High risk types (particularly 16 and 18)–cervical cell abnormalities–certain anogenital cancers
Low risk types (particularly 6 and 11)–cervical cell abnormalities- usually
resolve spontaneously and do not lead to cancer
–genital warts–respiratory papillomatosis
InitialHPV
Infection
Cleared HPV Infection
Within 1 Year 1-5 YearsUp to Decades
PersistentInfection
CIN 2/3
Cervical Cancer
CIN 1
Natural History of HPV Infection
Cancer
Cervical
Anal
Vulvar/vaginal
Penile
Oral/pharynx
Cancer Attributable to HPV - 2006
Cancer
Cases
12,000
3,700
4,480
1,000
10,000
Attributable
Fraction
100%
90%
40%
40%
12%
HPV-associated Conditions
HPV 16, 18
Cervical cancer
- High/low grade cervical
abnormalities
Anal, Vulvar, Vaginal, Penile
Head and neck cancers
HPV 6, 11
Low grade cervical
abnormalities
Genital warts
RRP
Estimated %
70%
30%-50%
10%
10%
90%90%
Global distribution of HPV types in cervical cancer
53%
15%
9%
6%
3%
14%
HPV 16
HPV 18
HPV 45
HPV 31
HPV 33
HPV others
Human Papilloma Virus Vaccine
• Contains the L1 protein from four types of HPV (16, 18, 6, 11)
• Produced using recombinant DNA technology
• L1 proteins self assemble into non-infectious units called virus-like particles (VLPs)
• VLPs are highly immunogenic
HPV Vaccines
Yeast Cell Culture
• L1 VLPs made in insect cells –
GSK 16 and 18 - Cervarix• i.m. 3 shots 0, 1 and 6 month
• VLPs made in yeast cells – • Merck 16,18,11 and 6 -Gardasil• i.m. 3 shots 0, 2 and 6 month
Insect Cell Culture
HPV vaccine news headlines •“Vaccine prevents most cervical cancers.”
- New York Times, October 7, 2005.
•Vaccine proves 100 percent effective in preventing cervical cancer – Seattle Times, October 6, 2005.
•“Promising new vaccines could wipe out cervical cancer. But they must be administered to preteens, and some groups oppose that.” – Philadelphia Inquirer, July 4, 2005.
•“OK Roll up your sleeve; new vaccines are arriving but the economics are still a challenge” –Business Week, July 25, 2005.
Efficacy of HPV Vaccine Among 16-26 year-old Females*
Endpoint
Vaccine
N Cases
Placebo
N Cases Efficacy (95% CI)
HPV 16/18-related
CIN2/3 or AIS8487 0 8460 53 100 (93,100)
HPV 6/11/16/18
related CIN7858 4 7861 83 95 (87, 99)
HPV 6/11/16/18
related genital warts
7897 17899 91 99 (94,100)
*Package insert: Gardasil® . . Integrated dataset; results in the per-protocol populations CIN – cervical intraepithelial neoplasia; AIS – adenocarcinoma in situ
Human Papillomavirus Vaccine Efficacy
• High efficacy among females without evidence of infection with vaccine HPV types
• No evidence that the vaccine had efficacy against existing disease or infection
• Prior infection with one HPV type did not diminish efficacy of the vaccine against other vaccine HPV types
HPV Vaccine Schedule
• Approved for females 9-26 year of age
• 3 doses at 0, 2, and 6 months
• Minimum intervals:
–4 weeks between doses 1 and 2
–12 weeks between doses 2 and 3
HPV Vaccine – Provisional ACIP Recommendations
• Routine vaccination of ♂ at 12 years of age
• The vaccination series can be started as young as 9 years of age at the clinician's discretion
• Vaccination is recommended for females 13-26 years of age who have not been previously vaccinated
• Ideally vaccine should be administered before onset of sexual activity
• Females who are sexually active should be vaccinated
HPV Vaccine – Special Situations*
• Females 26 years of age or younger with, equivocal or abnormal Pap test, positive HPV DNA, and genital warts may be vaccinated
• Vaccine will have no effect on existing disease or infection
*Provisional ACIP recommendation, June 2006
HPV Vaccine – Special Situations*
• Females 26 years of age or younger who are lactating/breastfeeding or are immuno-compromised may be vaccinated
• NOT recommended for pregnant women
*Provisional ACIP recommendation, June 2006
Screening for Cervical Cancer
• Why get screened?
• Screening was developed to detect abnormal cervical cells in the early stages when it is easy to remove them
• Who should be screened?
• Women from 25-65 years
• Once every 3 years
HPV Vaccine and Cervical Cancer Screening
• Cervical cancer screening recommendations have NOT changed for females who receive HPV vaccine– 30% of cervical cancers caused by HPV types
are not prevented by the quadrivalent HPV vaccine
– Vaccinated females could subsequently be infected with non-vaccine HPV types
– Sexually active females could have been infected prior to vaccination
• Providers should educate women about the importance of cervical cancer screening
Adding up the facts
• HPV is present in the majority of sexually active adults
• Presence of HPV does not indicate promiscuity
• HPV is short lived and asymptomatic in most adults
• If high risk HPV (16 and 18) persists – can cause Ca CX
• Cervical cancer kill 200,000 women worldwide annually
• 70% of Ca Cx is due to HPV 16 and 18 types
• HPV vaccine given at age 11, eliminates 70% of Ca Cx
• HPV vaccine does not replace screening for Ca Cx
• HPV vaccine in men prevents Ca Penis and genital warts
• Rapid adoption of HPV vaccine is right and essential
US National Immunization Program
• Hotline (800) CDC-INFO
• Email [email protected]
• Website www.cdc.gov/nip
• Broadcast Updates and Resources Web Page
www.cdc.gov/nip/ed/UpdatesandResources.htm